Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros











Intervalo de año de publicación
1.
Atherosclerosis ; 288: 51-59, 2019 09.
Artículo en Inglés | MEDLINE | ID: mdl-31323462

RESUMEN

BACKGROUND AND AIMS: Epicardial adipose tissue (EAT) is a visceral AT, surrounding myocardium and coronary arteries. Its volume is higher in Type 2 diabetic (DM2) patients, associated with cardiovascular disease risk. Lipoprotein lipase (LPL) hydrolyses triglycerides (TG) from circulating lipoproteins, supplying fatty acids to AT, contributing to its expansion. We aimed to evaluate LPL expression and activity in EAT from DM2 and no DM2 patients, and its regulators ANGPTL4, GPIHBP1 and PPARγ levels, together with VLDLR expression and EAT LPL association with VLDL characteristics. METHODS: We studied patients undergoing coronary by-pass graft (CABG) divided into CABG-DM2 (n = 21) and CABG-noDM2 (n = 29), and patients without CABG (No CABG, n = 30). During surgery, EAT and subcutaneous AT (SAT) were obtained, in which LPL activity, gene and protein expression, its regulators and VLDLR protein levels were determined. Isolated circulating VLDLs were characterized. RESULTS: EAT LPL activity was higher in CABG-DM2 compared to CABG-noDM2 and No CABG (p=0.002 and p<0.001) and in CABG-noDM2 compared to No CABG (p=0.02), without differences in its expression. ANGPTL4 levels were higher in EAT from No CABG compared to CABG-DM2 and CABG-noDM2 (p<0.001). GPIHBP1 levels were higher in EAT from CABG-DM2 and CABG-noDM2 compared to No CABG (p= 0.04). EAT from CABG-DM2 presented higher PPARγ levels than CABG-noDM2 and No CABG (p=0.02 and p=0.03). No differences were observed in VLDL composition between groups, although EAT LPL activity was inversely associated with VLDL-TG and TG/protein index (p<0.05). CONCLUSIONS: EAT LPL regulation would be mainly post-translational. The higher LPL activity in DM2 could be partly responsible for the increase in EAT volume.


Asunto(s)
Proteína 4 Similar a la Angiopoyetina/análisis , Diabetes Mellitus Tipo 2/enzimología , Grasa Intraabdominal/enzimología , Lipoproteína Lipasa/análisis , Receptores de Lipoproteína/análisis , Adiposidad , Anciano , Estudios de Casos y Controles , Diabetes Mellitus Tipo 2/diagnóstico , Diabetes Mellitus Tipo 2/fisiopatología , Activación Enzimática , Ácidos Grasos/sangre , Femenino , Humanos , Grasa Intraabdominal/fisiopatología , Lipoproteínas VLDL/sangre , Masculino , Persona de Mediana Edad , PPAR gamma/metabolismo , Pericardio , Receptores de LDL/análisis , Triglicéridos/sangre
2.
São Paulo; s.n; s.n; 2019. 72 p. ilus, graf, tab.
Tesis en Portugués | LILACS | ID: biblio-999825

RESUMEN

A hipercolesterolemia familial (HF) é uma doença autossômica dominante considerada como uma das formas mais graves de hiperlipidemia, assim como, a principal causa de morbi-mortalidade por ser o principal fator desencadeante da aterosclerose. A alteração primária e mais freqüente da HF incide no gene do receptor da LDL (LDLr), sabe-se que mais de 1600 mutações são descritas na literatura e a principal consequência dessas alterações resultam no comprometimento da remoção da LDL, aumentando a concentração plasmática. Atualmente, o ultrasequenciamento genômico permite gerar muitos dados, que podem identificar novas mutações gênicas de forma eficiente, reprodutiva e rápida. No entanto, somente a validação da nova mutação por atividade funcional pode realmente estabelecer a associação com a doença. O presente estudo tem como objetivo realizar a análise da atividade do receptor da LDL, identificadas através do sequenciamento de alto rendimento, no gene LDLr realizado pelo nosso grupo de pesquisa e correlacionar com dados clínicos, in vitro, in silico e estrutural. Para cumprir esta meta, os linfócitos T dos portadores de HF foram isolados do sangue periférico, cultivados e submetidos a estímulo para a expressão de receptores da LDL, incubados com LDL marcada para avaliação de ligação e interiorização pelas células de cada paciente. Dos 30 pacientes selecionados para esse estudo, 63% apresentaram mutação no LDLR, sendo que quase todas as variantes (p.Gly373Asp, p.Asp601His, p.Ile488Thr, p.Gly549Asp, p.Gly592Glu e Gly681Asp) são localizadas no segundo domínio entre os éxons 7 ao 14. De acordo com o docking molecular a variante p.Gly592Glu (rs137929307), que já foi identificada na população polonesa, espanhola e brasileira, já relacionada com a HF, pode aumentar a interação do LDLr com a ApoB e consequentemente o modo de interação entre as proteínas, no estudo in vitro foi possível notar um aumento tanto na média de fluorescência da ligação e da ligação e interiorização em relação a quantidade de LDLr na superfície celular


Familial hypercholesterolemia (HF) is an autosomal dominant disease considered as one of the most severe forms of hyperlipidemia, as well as the main cause of morbidity and mortality because it is the main triggering factor for atherosclerosis. The primary and more frequent alteration of the HF affects the LDL receptor gene (LDLr), it is known that more than 1600 mutations are described in the literature and the main consequence of these alterations results in the compromise of the LDL removal, increasing the plasma concentration. Nowadays, genomic ultrasequencing allows the generation of many data, which can identify new gene mutations efficiently, reproductively and rapidly. However, only the validation of the new functional activity mutation can actually establish association with the disease. The aim of the present study was to analyze LDL receptor activity, identified by high-throughput sequencing, in the LDLr gene performed by our research group and to correlate with clinical, in vitro, in silico and structural data. To meet this goal, the T lymphocytes from the HF carriers were isolated from the peripheral blood, cultured and challenged for the expression of LDL receptors, incubated with labeled LDL for binding assessment and internalization by the cells of each patient. Of the 30 patients selected for this study, 63% had a mutation in LDLR, and almost all variants (p.Gly373Asp, p.Asp601His, p.Ile488Thr, p.Gly549Asp, p.Gly592Glu and Gly681Asp) are located in the second domain between exons 7 to 14. According to the molecular docking the variant p.Gly592Glu (rs137929307), which has already been identified in the Polish, Spanish and Brazilian population, already related to HF, can increase the interaction of LDLr with ApoB and consequently the mode of interaction between proteins, in the in vitro study it was possible to note an increase in both the mean fluorescence of binding and binding and internalization in relation to the amount of LDLr on the cell surface


Asunto(s)
Humanos , Masculino , Femenino , Adulto , Receptores de LDL/análisis , Estudio de Validación , Lipoproteínas LDL/análisis , Linfocitos , Simulación del Acoplamiento Molecular , Hiperlipoproteinemia Tipo II/clasificación
3.
Rev. bras. anal. clin ; 32(3): 195-9, 2000. ilus, graf
Artículo en Portugués | LILACS | ID: lil-296349

RESUMEN

Foi otimizado o método de RT-PCR para avaliar a expressäo gênica do recptor de LDL (RLDL) em células mononucleares periféricas (CMP), provenientes de indivíduos hipercolesterolêmicos tratados com agentes hipolipemiantes. As CMP foram isoladas a partir de 10 mL de sangue periférico por centrifugaçäo sob gradiente de Ficoll-Paque Plus. O RNA total foi extraído utilizando o reagente Trizol, ressuspendido em água tratada com DEPC e quantificado por espectrofotometria a 260 nm. O cDNA foi sintetizado a partir de 1 µg de RNA utilizando a enzima SuperScript TM II RT RNAse-. A seguir, o gene do RLDL foi amplificado pela técnica de PCR. Os produtos de amplificaçäo foram avaliados por eletroforese em gel de agarose a 1,5 por cento e fotografados. Os genes da gliceraldeído-3-fosfato desidrogenase (GAPDH) e da ß-actina foram amplificados como controles internos utilizando a mesma metodologia descrita. A expressäo gênica do RLDL foi determinada pelas relaçöes entre a intensidade das bandas dos produtos amplificados do RLDL e GAPDH (RLDL/GAPDH) e do RLDL e ß-actina (RLDL/ß-actina), determinadas por densitometria das fotografias. Em resumo, o método otimizado permite a rápida avaliaçäo da expressäo gênica do RLDL em CMP, sem a necessidade de componentes radioativos.


Asunto(s)
Humanos , Masculino , Femenino , Expresión Génica , Hipercolesterolemia/diagnóstico , Leucocitos Mononucleares/citología , Optimización de Procesos , Receptores de LDL/análisis , Anticolesterolemiantes/administración & dosificación , Homeostasis , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa
4.
Cell Immunol ; 167(1): 18-29, 1996 Jan 10.
Artículo en Inglés | MEDLINE | ID: mdl-8548841

RESUMEN

Low-density lipoprotein receptors (LDLR) have been shown to be expressed, internalized, and transcribed in CD3-CD16+CD56+ cells. Only a low percentage (up to 12%) of NK cells express LDLR. Interleukin 2 (IL-2) (1000 IU/ml) induced a threefold increase in the expression of LDLR on the cell surface that results from, at least in part, augmentation of LDLR turnover from the cytosol to the membrane. Scatchard analysis revealed that IL-2 decreased the Kd of LDLR binding for LDL from 7.53 to 4.33 nM with an increment in the number of binding sites from 2500 up to 5000. Both the proliferative response and cytotoxic functions of these cells are affected by LDL. Low concentrations of LDL induce an increase in the proliferative response (up to eightfold) and in the cytotoxic response of NK cells (up to fivefold). High concentration (more than 60 micrograms/ml) of LDL hampers both proliferative response and cytotoxic activity of NK cells. LDL did not affect the cytotoxic functions of IL-2-activated NK cells. Overall, we have shown that LDLR is expressed on the surface of NK cells and can be augmented by IL-2. Furthermore, we propose some insights into the mechanism responsible for the enhanced expression of LDLR on NK cell surface. In addition, our data clearly delineate that LDLR plays an important role in the regulation of proliferative responses and cytotoxic activity of these cells.


Asunto(s)
Complejo CD3/análisis , Antígeno CD56/análisis , Interleucina-2/farmacología , Células Asesinas Naturales/química , Receptores de IgG/análisis , Receptores de LDL/análisis , Humanos , Lipoproteínas LDL/metabolismo , Activación de Linfocitos , Receptores de LDL/fisiología
5.
J Pediatr ; 120(6): 892-8, 1992 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-1593349

RESUMEN

We evaluated the safety and efficacy of dextran sulfate low-density lipoprotein (LDL) apheresis in the treatment of three children (aged 6, 7, and 10 years) with severe familial homozygous hypercholesterolemia and undetectable LDL receptor activity. A total of 35 double plasma volume procedures were performed. The ranges of the mean decreases of the three patients in plasma lipid concentrations after LDL apheresis (p less than 0.0001) were as follows: total cholesterol, 76% to 79%; LDL-cholesterol, 78% to 81%; very low density lipoprotein cholesterol, 69% to 75%; high-density lipoprotein cholesterol, 27% to 40%; and triglycerides, 34% to 68%. There were statistically significant but clinically and biologically irrelevant changes in hematologic indexes, serum chemistry values, immunoglobulin levels, complement activity, and plasma concentrations of fat-soluble vitamins. Simple correlation analysis of the variables affecting total cholesterol removal showed significant correlation coefficients (r values) for preapheresis total cholesterol values (r = 0.70; p less than 0.01) and preapheresis LDL-cholesterol values (r = 0.61; p less than 0.01). A multiple regression model explained 82% of the variance based on the preapheresis cholesterol concentration, volume of whole blood processed, and the serum albumin concentration. Side effects of the LDL-apheresis treatments were rare and included abdominal cramping and urticaria. Two procedures were aborted because of intravenous access problems in the younger children. This study confirms that LDL apheresis using a dextran sulfate affinity column is efficacious in rapidly lowering total and LDL-cholesterol concentrations. Furthermore, the procedure is safe and well tolerated by children as young as 6 years of age. This treatment may prevent the progression of atherosclerosis in children with homozygous familial hypercholesterolemia and may therefore avert early death.


Asunto(s)
Eliminación de Componentes Sanguíneos , Hiperlipoproteinemia Tipo II/terapia , Lipoproteínas LDL/sangre , Niño , Cromatografía de Afinidad , Sulfato de Dextran , Filtración , Homocigoto , Humanos , Hiperlipoproteinemia Tipo II/genética , Receptores de LDL/análisis
6.
Mol Biochem Parasitol ; 28(2): 145-52, 1988 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-3367933

RESUMEN

Schistosomula of Schistosoma mansoni were shown to contain proteins on their surface membranes which bind iodinated human low density lipoproteins (125I-LDL). Treatment of the parasites with trypsin decreased the binding in comparison with untreated controls. Membrane-bound, acetone-insoluble proteins were extracted from the schistosomula with Triton X-100 and the extract in liposome form was incubated with 125I-LDL at room temperature. After incubation a complex was formed between the proteins present in the extract and 125I-LDL, as shown by a filter binding assay. 125I-LDL binding to filters was proportional to the amount of protein in the extract; it was inhibited by unlabelled LDL and VLDL and by EDTA. Binding of 125I-LDL to proteins present in the liposome suspension containing the Triton X-100 extract followed saturation kinetics, indicating the occurrence of receptors for lipoproteins in the extract.


Asunto(s)
Receptores de LDL/análisis , Schistosoma mansoni/metabolismo , Animales , Cinética , Receptores de LDL/efectos de los fármacos , Receptores de LDL/metabolismo , Schistosoma mansoni/análisis , Schistosoma mansoni/efectos de los fármacos , Tripsina/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA